MoonLake Immunotherapeutics(MLTX),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community - To The Moon

At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.

Close

MLTX MoonLake Immunotherapeutics

Trading 03-19 09:40:56 EDT

16.64

+0.41

+2.50%

High17.20	Low16.55	Vol122.06K
Open17.09	D1 Closing16.23	Amplitude4.00%
Mkt Cap1.19B	Tradable Cap672.32M	Total Shares71.37M
T/O2.07M	T/O Rate0.30%	Tradable Shares40.42M
P/B--	ROE--	EPS0.00
52wk High--	52wk Low--	P/E--
Dividend--	Div.Yield--	ROA--

Loading ...

{"stockData":{"symbol":"MLTX","market":"US","secType":"STK","nameCN":"MoonLake Immunotherapeutics","latestPrice":16.635,"timestamp":1773927654020,"preClose":16.23,"halted":0,"volume":122064,"delay":0,"changeRate":0.024953789279112824,"floatShares":40415700,"shares":71373579,"eps":-3.529999,"marketStatus":"Trading","change":0.405,"latestTime":"03-19 09:40:56 EDT","open":17.09,"high":17.2,"low":16.55,"amount":2073753.23016,"amplitude":0.040049,"askPrice":16.7,"askSize":450,"bidPrice":16.57,"bidSize":438,"shortable":3,"etf":0,"ttmEps":-3.529999,"tradingStatus":2,"nextMarketStatus":{"tag":"Post-Mkt","tradingStatus":3,"beginTime":1773950400000},"marketStatusCode":2,"adr":0,"listingDate":1603166400000,"exchange":"NASDAQ","adjPreClose":16.23,"preHourTrading":{"tag":"盘前","latestPrice":17.08,"preClose":16.23,"latestTime":"09:29 EDT","volume":15765,"amount":265972.54467000003,"timestamp":1773926999999,"change":0.85,"changeRate":0.052372,"amplitude":0.027726},"postHourTrading":{"tag":"盘后","latestPrice":16.2075,"preClose":16.23,"latestTime":"19:58 EDT","volume":21184,"amount":343890.4782,"timestamp":1773878321962,"change":-0.0225,"changeRate":-0.001386,"amplitude":0.014941},"volumeRatio":5.665746,"impliedVol":0.7401,"impliedVolPercentile":0.3466},"requestUrl":"/m/hq/s/MLTX/tweets","defaultTab":"tweets","newsList":[{"id":"2620243369","title":"MoonLake upgraded to Buy from Neutral at Rothschild & Co Redburn","url":"https://stock-news.laohu8.com/highlight/detail?id=2620243369","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2620243369?lang=en_us&edition=fundamental","pubTime":"2026-03-19 16:50","pubTimestamp":1773910228,"startTime":"0","endTime":"0","summary":"Rothschild & Co Redburn analyst Qize Ding upgraded MoonLake Immunotherapeutics (MLTX) to Buy from Neutral with a price target of $40, up from $12. ...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/moonlake-upgraded-to-buy-from-neutral-at-rothschild-co-redburn-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/moonlake-upgraded-to-buy-from-neutral-at-rothschild-co-redburn-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4139","MLTX"],"gpt_icon":0},{"id":"2619016301","title":"MoonLake Immunotherapeutics: Sonelokimab’s Differentiated IL‑17A/F Profile and Multibillion-Dollar Potential Underpin Buy Rating Despite HS Trial Concerns","url":"https://stock-news.laohu8.com/highlight/detail?id=2619016301","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2619016301?lang=en_us&edition=fundamental","pubTime":"2026-03-13 14:05","pubTimestamp":1773381924,"startTime":"0","endTime":"0","summary":"TD Cowen analyst Phil Nadeau has maintained their bullish stance on MLTX stock, giving a Buy rating on March 11. Phil Nadeau has given his Buy rati...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/ratings/moonlake-immunotherapeutics-sonelokimabs-differentiated-il‑17a-f-profile-and-multibillion-dollar-potential-underpin-buy-rating-despite-hs-trial-concerns-ratings-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/ratings/moonlake-immunotherapeutics-sonelokimabs-differentiated-il‑17a-f-profile-and-multibillion-dollar-potential-underpin-buy-rating-despite-hs-trial-concerns-ratings-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["MLTX"],"gpt_icon":0},{"id":"2618941636","title":"MoonLake Immunotherap Is Maintained at Buy by Clear Street","url":"https://stock-news.laohu8.com/highlight/detail?id=2618941636","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2618941636?lang=en_us&edition=fundamental","pubTime":"2026-03-11 19:25","pubTimestamp":1773228300,"startTime":"0","endTime":"0","summary":"Ratings actions from Benzinga: https://www.benzinga.com/quote/MLTX/analyst-ratings \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  March 11, 2026 07:25 ET (11:25 GMT)","market":"other","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["MLTX","BK4139"],"gpt_icon":0},{"id":"2618294136","title":"Analysts Conflicted on These Healthcare Names: MoonLake Immunotherapeutics (MLTX), Sarepta Therapeutics (SRPT) and vTv Therapeutics (VTVT)","url":"https://stock-news.laohu8.com/highlight/detail?id=2618294136","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2618294136?lang=en_us&edition=fundamental","pubTime":"2026-03-11 19:11","pubTimestamp":1773227469,"startTime":"0","endTime":"0","summary":"Analysts have been eager to weigh in on the Healthcare sector with new ratings on MoonLake Immunotherapeutics (MLTX – Research Report), Sarepta The...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/analysts-conflicted-on-these-healthcare-names-moonlake-immunotherapeutics-mltx-sarepta-therapeutics-srpt-and-vtv-therapeutics-vtvt-blurbs-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/analysts-conflicted-on-these-healthcare-names-moonlake-immunotherapeutics-mltx-sarepta-therapeutics-srpt-and-vtv-therapeutics-vtvt-blurbs-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["HCSG","BK4585","IE00BFTCPJ56.SGD","VTVT","IE00B2B36J28.USD","SRPT","LU0128526141.USD","LU0029874061.USD","MLTX","BK4137","IE00BJT1NW94.SGD","XLV","IE0002141913.USD","IE0009355771.USD","SRPU","XBI","BK4581","IE00BJJMRZ35.SGD","BK4588","LABU","BK4139"],"gpt_icon":0},{"id":"2618946983","title":"MoonLake price target raised to $70 from $45 at Clear Street","url":"https://stock-news.laohu8.com/highlight/detail?id=2618946983","media":"TIPRANKS","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2618946983?lang=en_us&edition=fundamental","pubTime":"2026-03-11 18:36","pubTimestamp":1773225397,"startTime":"0","endTime":"0","summary":"Clear Street analyst Kaveri Pohlman raised the firm’s price target on MoonLake Immunotherapeutics (MLTX) to $70 from $45 and keeps a Buy rating on ...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/moonlake-price-target-raised-to-70-from-45-at-clear-street-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/moonlake-price-target-raised-to-70-from-45-at-clear-street-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4139","MLTX"],"gpt_icon":0},{"id":"2616364040","title":"MoonLake Immunotherapeutics (MLTX) Is Down 6.3% After Wider 2025 Loss And SLK BLA Timeline Update – Has The Bull Case Changed?","url":"https://stock-news.laohu8.com/highlight/detail?id=2616364040","media":"Simply Wall St.","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2616364040?lang=en_us&edition=fundamental","pubTime":"2026-03-03 06:15","pubTimestamp":1772489724,"startTime":"0","endTime":"0","summary":"MoonLake Immunotherapeutics recently reported full-year 2025 results showing a wider net loss of US$227.32 million and a basic loss per share of US$3.53, while highlighting progress in developing its lead drug candidate, Sonelokimab (SLK), across several inflammatory disease indications.\nThe company’s latest filings and updates emphasize FDA and EMA engagement, multiple positive late-stage trial readouts, and a planned SLK Biologics License Application submission in the second half of 2026...","market":"nz","thumbnail":"https://images.simplywall.st/asset/industry/6111000-choice2-main-header/1585186599552","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/6111000-choice2-main-header/1585186599552"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-mltx/moonlake-immunotherapeutics/news/moonlake-immunotherapeutics-mltx-is-down-63-after-wider-2025","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-mltx/moonlake-immunotherapeutics/news/moonlake-immunotherapeutics-mltx-is-down-63-after-wider-2025","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["BK4139","MLTX","SLK.AU"],"gpt_icon":0},{"id":"2616533024","title":"MoonLake Immunotherap Is Maintained at Buy by HC Wainwright & Co.","url":"https://stock-news.laohu8.com/highlight/detail?id=2616533024","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2616533024?lang=en_us&edition=fundamental","pubTime":"2026-03-02 21:48","pubTimestamp":1772459280,"startTime":"0","endTime":"0","summary":"Ratings actions from Benzinga: https://www.benzinga.com/quote/MLTX/analyst-ratings \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  March 02, 2026 08:48 ET (13:48 GMT)","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","MLTX"],"gpt_icon":0},{"id":"2616597743","title":"RBC Raises Price Target on MoonLake Immunotherapeutics to $13 From $12, Keeps Sector Perform, Speculative Risk","url":"https://stock-news.laohu8.com/highlight/detail?id=2616597743","media":"MT Newswires Live","labels":["express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2616597743?lang=en_us&edition=fundamental","pubTime":"2026-03-02 21:27","pubTimestamp":1772458077,"startTime":"0","endTime":"0","summary":"MoonLake Immunotherapeutics (MLTX) has an average rating of overweight and mean price target of $27.15, according to analysts polled by FactSet.(MT Newswires covers equity, commodity and economic rese","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate","earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"express","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["MLTX"],"gpt_icon":0},{"id":"2616733105","title":"RBC Capital Keeps Their Hold Rating on MoonLake Immunotherapeutics (MLTX)","url":"https://stock-news.laohu8.com/highlight/detail?id=2616733105","media":"TIPRANKS","labels":["express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2616733105?lang=en_us&edition=fundamental","pubTime":"2026-03-02 20:19","pubTimestamp":1772453999,"startTime":"0","endTime":"0","summary":"RBC Capital analyst Brian Abrahams maintained a Hold rating on MoonLake Immunotherapeutics on February 27 and set a price target of $13.00. The com...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/rbc-capital-keeps-their-hold-rating-on-moonlake-immunotherapeutics-mltx-blurbs-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":["rate","earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/rbc-capital-keeps-their-hold-rating-on-moonlake-immunotherapeutics-mltx-blurbs-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"express","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["MLTX"],"gpt_icon":0},{"id":"2616335067","title":"MoonLake Immunotherapeutics price target raised to $40 from $32 at H.C. Wainwright","url":"https://stock-news.laohu8.com/highlight/detail?id=2616335067","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2616335067?lang=en_us&edition=fundamental","pubTime":"2026-03-02 19:16","pubTimestamp":1772450178,"startTime":"0","endTime":"0","summary":"H.C. Wainwright raised the firm’s price target on MoonLake Immunotherapeutics (MLTX) to $40 from $32 and keeps a Buy rating on the shares. The firm...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/moonlake-immunotherapeutics-price-target-raised-to-40-from-32-at-h-c-wainwright-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/moonlake-immunotherapeutics-price-target-raised-to-40-from-32-at-h-c-wainwright-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["MLTX"],"gpt_icon":0},{"id":"2616335974","title":"MoonLake Immunotherapeutics : H.c. Wainwright Raises Target Price to $40 From $32","url":"https://stock-news.laohu8.com/highlight/detail?id=2616335974","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2616335974?lang=en_us&edition=fundamental","pubTime":"2026-03-02 19:12","pubTimestamp":1772449960,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260302:nAZN4SJ4IA:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["MLTX","BK4139"],"gpt_icon":0},{"id":"2616416876","title":"Analysts Have Conflicting Sentiments on These Healthcare Companies: MoonLake Immunotherapeutics (MLTX) and Genfit (OtherGNFTF)","url":"https://stock-news.laohu8.com/highlight/detail?id=2616416876","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2616416876?lang=en_us&edition=fundamental","pubTime":"2026-03-02 03:10","pubTimestamp":1772392207,"startTime":"0","endTime":"0","summary":"Companies in the Healthcare sector have received a lot of coverage today as analysts weigh in on MoonLake Immunotherapeutics (MLTX – Research Repor...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/analysts-have-conflicting-sentiments-on-these-healthcare-companies-moonlake-immunotherapeutics-mltx-and-genfit-othergnftf-blurbs-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/analysts-have-conflicting-sentiments-on-these-healthcare-companies-moonlake-immunotherapeutics-mltx-and-genfit-othergnftf-blurbs-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["XLV","LABU","MLTX","BK4585","BK4588","XBI","BK4581","BK4137","HCSG","BK4139","LU0029874061.USD","LU0128526141.USD","GNFTF"],"gpt_icon":0},{"id":"2614418460","title":"MoonLake Immunotherapeutics price target raised to $11 from $10 at Goldman Sachs","url":"https://stock-news.laohu8.com/highlight/detail?id=2614418460","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2614418460?lang=en_us&edition=fundamental","pubTime":"2026-02-26 20:31","pubTimestamp":1772109076,"startTime":"0","endTime":"0","summary":"Goldman Sachs raised the firm’s price target on MoonLake Immunotherapeutics (MLTX) to $11 from $10 and keeps a Sell rating on the shares. MoonLake ...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/moonlake-immunotherapeutics-price-target-raised-to-11-from-10-at-goldman-sachs-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/moonlake-immunotherapeutics-price-target-raised-to-11-from-10-at-goldman-sachs-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["MLTX"],"gpt_icon":0},{"id":"2614486070","title":"MoonLake Immunotherap Price Target Maintained With a $25.00/Share by Needham","url":"https://stock-news.laohu8.com/highlight/detail?id=2614486070","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2614486070?lang=en_us&edition=fundamental","pubTime":"2026-02-26 19:24","pubTimestamp":1772105040,"startTime":"0","endTime":"0","summary":"Ratings actions from Benzinga: https://www.benzinga.com/quote/MLTX/analyst-ratings \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  February 26, 2026 06:24 ET (11:24 GMT)","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["MLTX","BK4139"],"gpt_icon":0},{"id":"2614085617","title":"MoonLake posts FY 2025 interest expense of USD 7.2 million","url":"https://stock-news.laohu8.com/highlight/detail?id=2614085617","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2614085617?lang=en_us&edition=fundamental","pubTime":"2026-02-25 19:13","pubTimestamp":1772018026,"startTime":"0","endTime":"0","summary":"Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Moonlake Immunotherapeutics published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on February 25, 2026, and is solely responsible for the information contained therein.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260225:nNDL230Gml:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["MLTX","BK4139"],"gpt_icon":0},{"id":"2613972711","title":"MoonLake Immunotherapeutics price target raised to $35 from $30 at Oppenheimer","url":"https://stock-news.laohu8.com/highlight/detail?id=2613972711","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2613972711?lang=en_us&edition=fundamental","pubTime":"2026-02-24 20:54","pubTimestamp":1771937650,"startTime":"0","endTime":"0","summary":"Oppenheimer raised the firm’s price target on MoonLake Immunotherapeutics (MLTX) to $35 from $30 and keeps an Outperform rating on the shares. Moon...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/moonlake-immunotherapeutics-price-target-raised-to-35-from-30-at-oppenheimer-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/moonlake-immunotherapeutics-price-target-raised-to-35-from-30-at-oppenheimer-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["MLTX","OPY"],"gpt_icon":0},{"id":"2613715490","title":"MoonLake Immunotherapeutics : Leerink Partners Raises Target Price to $24 From $20","url":"https://stock-news.laohu8.com/highlight/detail?id=2613715490","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2613715490?lang=en_us&edition=fundamental","pubTime":"2026-02-24 20:05","pubTimestamp":1771934715,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260224:nFWN3ZK0XH:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["MLTX","BK4139"],"gpt_icon":0},{"id":"2613794758","title":"MoonLake Immunotherap Is Maintained at Buy by Needham","url":"https://stock-news.laohu8.com/highlight/detail?id=2613794758","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2613794758?lang=en_us&edition=fundamental","pubTime":"2026-02-24 18:05","pubTimestamp":1771927500,"startTime":"0","endTime":"0","summary":"Ratings actions from Benzinga: https://www.benzinga.com/quote/MLTX/analyst-ratings \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  February 24, 2026 05:05 ET (10:05 GMT)","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","MLTX"],"gpt_icon":0},{"id":"2613773404","title":"Needham Raises MoonLake Immunotherapeutics' Price Target to $25 From $20, Buy Rating Kept","url":"https://stock-news.laohu8.com/highlight/detail?id=2613773404","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2613773404?lang=en_us&edition=fundamental","pubTime":"2026-02-24 03:58","pubTimestamp":1771876684,"startTime":"0","endTime":"0","summary":"MoonLake Immunotherapeutics (MLTX) has an average rating of overweight and mean price target of $22.21, according to analysts polled by FactSet.(MT Newswires covers equity, commodity and economic rese","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["MLTX"],"gpt_icon":0},{"id":"2613731132","title":"Analysts Offer Insights on Healthcare Companies: MoonLake Immunotherapeutics (MLTX) and PROCEPT BioRobotics (PRCT)","url":"https://stock-news.laohu8.com/highlight/detail?id=2613731132","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2613731132?lang=en_us&edition=fundamental","pubTime":"2026-02-24 02:30","pubTimestamp":1771871408,"startTime":"0","endTime":"0","summary":"There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on MoonLake Immunotherapeutics (MLTX – Research Report)...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/analysts-offer-insights-on-healthcare-companies-moonlake-immunotherapeutics-mltx-and-procept-biorobotics-prct-blurbs-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/analysts-offer-insights-on-healthcare-companies-moonlake-immunotherapeutics-mltx-and-procept-biorobotics-prct-blurbs-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4588","XLV","LU0128526141.USD","PRCT","BK4082","XBI","BK4139","LABU","LU0029874061.USD","BK4137","BK4581","BK4585","MLTX","LU2324357040.USD","HCSG"],"gpt_icon":0}],"profile":{"websiteUrl":"http://www.moonlaketx.com","stockEarnings":[{"period":"1week","weight":-0.0902},{"period":"1month","weight":0.0292},{"period":"3month","weight":0.224},{"period":"6month","weight":-0.6982},{"period":"1year","weight":-0.5907},{"period":"ytd","weight":0.2314}],"compareEarnings":[{"period":"1week","weight":-0.022},{"period":"1month","weight":-0.0298},{"period":"3month","weight":-0.0222},{"period":"6month","weight":-0.0034},{"period":"1year","weight":0.179},{"period":"ytd","weight":-0.03}],"compareStock":{"symbol":"SPY","name":"SPDR S&P 500 ETF Trust"},"description":"MoonLake Immunotherapeutics, a clinical-stage biopharmaceutical company, engages in developing therapies. It is developing Sonelokimab, a novel investigational Nanobody for the treatment of inflammation diseases. The company is involved in conducting Phase II trials for hidradenitis suppurativa, psoriatic arthritis, ankylosing spondylitis, or axial spondyloarthritis. MoonLake Immunotherapeutics was incorporated in 2021 and is headquartered in Zug, Switzerland.","yearOnYearQuotes":[{"month":1,"riseRate":0.333333,"avgChangeRate":0.01118},{"month":2,"riseRate":0.5,"avgChangeRate":0.083781},{"month":3,"riseRate":0.5,"avgChangeRate":0.010205},{"month":4,"riseRate":0.2,"avgChangeRate":-0.112596},{"month":5,"riseRate":0.4,"avgChangeRate":0.086858},{"month":6,"riseRate":0.8,"avgChangeRate":0.175967},{"month":7,"riseRate":0.6,"avgChangeRate":0.073307},{"month":8,"riseRate":0.6,"avgChangeRate":0.090179},{"month":9,"riseRate":0.4,"avgChangeRate":-0.166769},{"month":10,"riseRate":0.6,"avgChangeRate":0.061028},{"month":11,"riseRate":0.666667,"avgChangeRate":0.098535},{"month":12,"riseRate":0.5,"avgChangeRate":0.079459}],"exchange":"NASDAQ","name":"MoonLake Immunotherapeutics","nameEN":"MoonLake Immunotherapeutics"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.36.2","shortVersion":"4.36.2","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"MoonLake Immunotherapeutics(MLTX),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","description":"Find the latest MoonLake Immunotherapeutics(MLTX) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","keywords":"MoonLake Immunotherapeutics,MLTX,MoonLake Immunotherapeutics股票,MoonLake Immunotherapeutics股票老虎,MoonLake Immunotherapeutics股票老虎国际,MoonLake Immunotherapeutics行情,MoonLake Immunotherapeutics股票行情,MoonLake Immunotherapeutics股价,MoonLake Immunotherapeutics股市,MoonLake Immunotherapeutics股票价格,MoonLake Immunotherapeutics股票交易,MoonLake Immunotherapeutics股票购买,MoonLake Immunotherapeutics股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"MoonLake Immunotherapeutics(MLTX),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","og_description":"Find the latest MoonLake Immunotherapeutics(MLTX) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","og_image":"https://community-static.tradeup.com/news/9b6dafd60190235ae8e2c95f52c583a0"}}}